Xenon filed a 2025 operating loss of $373.1 million, a 2025 net loss of $345.9 million and Q1 2026 cash of $545.9 million. The thesis depends on clinical execution, regulatory progress and how long the balance sheet can fund development.
References
Sources used in this report
SEC datasetSEC company tickers exchange datasetRetrieved 2026-05-20 · Issuer identity, ticker, exchange and CIKSEC APISEC submissions APIRetrieved 2026-05-20 · Filing chronology and company identitySEC XBRL APISEC companyfacts APIRetrieved 2026-05-20 · Financial statement cross-checksAnnual report2025 Form 10-K filed 2026-02-262026-02-26 · Annual business, risk and financial baselineQuarterly reportQ1 2026 Form 10-Q filed 2026-05-072026-05-07 · Latest interim financial baselineCurrent reportForm 8-K filed 2026-05-072026-05-07 · Recent current-report chronologyProxy statementDEF 14A filed 2026-04-222026-04-22 · Governance and incentive context